Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15695520 | 0.88 | KDM4E (0.41) | ALDH1A1GFERKDM4ELMNASYK | |
| SCHEMBL1234213 | 0.86 | ALDH1A1 (0.40) | ALDH1A1GFERHTTNPSR1TDP1 | |
| SCHEMBL24553727 | 0.76 | ALDH1A1 (0.44) | ALDH1A1GFERHTTNPSR1TDP1 | |
| SCHEMBL4563331 | 0.72 | AAK1 (0.39) | ALDH1A1MEN1KMT2AAAK1SYK | |
| SCHEMBL1234647 | 0.70 | CNR1 (0.33) | AAK1SYK | |
| SCHEMBL22657297 | 0.70 | ALDH1A1 (0.46) | ALDH1A1GFERHTTNPSR1TDP1 | |
| SCHEMBL30916019 | 0.68 | ALDH1A1 (0.46) | ALDH1A1GFERHTTNPSR1TDP1 | |
| SCHEMBL25056442 | 0.68 | ALDH1A1 (0.46) | ALDH1A1GFERHTTNPSR1TDP1 | |
| SCHEMBL24553575 | 0.68 | ALDH1A1 (0.46) | ALDH1A1GFERHTTNPSR1TDP1 | |
| SCHEMBL6133027 | 0.68 | ALDH1A1 (0.46) | ALDH1A1GFERHTTNPSR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1696912-B1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2016-05-11 | — | — | EP | disclosed |
| US-9145410-B2 | Pyrazolopyridines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-20120121651-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY | 2012-05-17 | — | — | US | disclosed |
| US-7879849-B2 | such as 1-(2-Methylpropyl)-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-amine, used as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090318435-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY | 2009-12-24 | — | — | US | disclosed |
| US-7544697-B2 | Pyrazolopyridines and analogs thereof | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20090075980-A1 | Pyrazolopyridines and Analogs Thereof | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| EP-1863809-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | Coley Pharmaceutical Group, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006107753-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| US-20060100229-A1 | Pyrazolopyridines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075980-A1 | Pyrazolopyridines and Analogs Thereof | IL4, IL4I1, IL2 | ALDH1A1 1406/4885GFER 3738/4885HTT 4235/4885 |
| US-20060100229-A1 | Pyrazolopyridines and analogs thereof | IL4, IL2, IL4I1 | ALDH1A1 1688/4885GFER 4298/4885HTT 3755/4885 |
| US-20120121651-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | IL4, IL4I1, IL2 | ALDH1A1 1406/4885GFER 3738/4885HTT 4235/4885 |
| US-20090318435-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | IL4, IL2, IL4I1 | ALDH1A1 1688/4885GFER 4298/4885HTT 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.